136 related articles for article (PubMed ID: 14608735)
1. [Visceral leishmaniasis in children: prognostic factors].
Abdelmoula MS; M'Hamdi Z; Amri F; Tebib N; Ben Turkia H; Ben Dridi MF
Tunis Med; 2003 Aug; 81(8):535-9. PubMed ID: 14608735
[TBL] [Abstract][Full Text] [Related]
2. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
3. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
4. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
[TBL] [Abstract][Full Text] [Related]
5. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
6. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
7. Visceral childhood leishmaniasis in southern Turkey: experience of twenty years.
Dursun O; Erişir S; Yeşilipek A
Turk J Pediatr; 2009; 51(1):1-5. PubMed ID: 19378883
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis: a common cause of post-infectious febrile pancytopenia in children in an endemic area: experience of a children's tertiary hospital.
Alexandropoulou O; Tsolia M; Kossiva L; Giannaki M; Karavanaki K
Pediatr Emerg Care; 2012 Jun; 28(6):533-7. PubMed ID: 22653455
[TBL] [Abstract][Full Text] [Related]
10. Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B.
Tavil B; Seçmeer G; Ozen H; Cengiz AB; Unal S; Gürgey A
Turk J Pediatr; 2008; 50(1):67-9. PubMed ID: 18365595
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for relapse of visceral leishmaniasis in Georgia.
Kajaia M; Morse DL; Kamkamidze G; Butsashvili M; Chubabria G; Zenaishvili O; Kokaia N; McNutt LA
Trop Med Int Health; 2011 Feb; 16(2):186-92. PubMed ID: 21143353
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda.
Mueller Y; Mbulamberi DB; Odermatt P; Hoffmann A; Loutan L; Chappuis F
Trop Med Int Health; 2009 Aug; 14(8):910-7. PubMed ID: 19552645
[TBL] [Abstract][Full Text] [Related]
13. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
14. Visceral leishmaniasis: bone marrow biopsy findings.
Kumar PV; Vasei M; Sadeghipour A; Sadeghi E; Soleimanpour H; Mousavi A; Tabatabaei AH; Rizvi MM
J Pediatr Hematol Oncol; 2007 Feb; 29(2):77-80. PubMed ID: 17279002
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis in Omani children: a review.
Elnour IB; Akinbami FO; Shakeel A; Venugopalan P
Ann Trop Paediatr; 2001 Jun; 21(2):159-63. PubMed ID: 11471261
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil.
Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M
Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017
[TBL] [Abstract][Full Text] [Related]
18. Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis.
Tapisiz A; Belet N; Ciftçi E; Ince E; Dogru U
J Trop Pediatr; 2007 Oct; 53(5):359-61. PubMed ID: 17626064
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
20. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
